Gamma Biosciences to acquire BioMagnetic Solutions
Gamma Biosciences has agreed to acquire BioMagnetic Solutions, a next-generation cell selection and bioseparation technology company.
Cognate BioServices expands manufacturing in U.S., Europe
Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
RoosterBio, Sartorius partner on cell and gene therapy manufacturing
RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cells manufacturing for regenerative medicines.
Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat patients has taken longer than expected. How to accelerate this process was the subject of a panel discussion on January 13 at the Biotech Showcase virtual event.  Discuss
Fujifilm secures funding, signs lease for new research/manufacturing center
Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and that a lease for a site in the Boston area has been signed.
Startup Creative Bio launches cell culture portfolio
Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
Bone Therapeutics, Rigenerand partner on cell therapy process development
Bone Therapeutics and Rigenerand have formed a cell therapy process development partnership.
Lentigen to manufacture vector for Oncternal
Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion. And developers of AI are becoming attractive acquisition targets for contract research organizations, according to Ulrik Kristensen, PhD, research analyst and founder of Emersion Insights.  Discuss
KSQ Therapeutics, Takeda to develop novel cancer immunotherapies
KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based therapies for cancer.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter